Shares of TG Therapeutics TGTX were up 5.9% yesterday after the company announced positive top-line data from a phase I study evaluating the subcutaneous (“SC”) formulation of its sole marketed drug, Briumvi (ublituximab-xiiy), in patients with myasthenia gravis (MG).
Simultaneously, the company also announced the initiation of a phase II study evaluating Briumvi as a maintenance therapy following induction with argenx’s ARGX blockbuster drug, Vyvgart (efgartigimod), in adult patients with MG.
Briumvi, an anti-CD20 monoclonal antibody, is currently approved for the treatment of adult patients with relapsing forms of multiple sclerosis (“RMS”) as an intravenous (IV) formulation.
In the phase I study, 11 patients with AChR antibody-positive MG received SC Briumvi across multiple cohorts. The treatment achieved drug levels in the body similar to those observed with the approved IV formulation of Briumvi.
The study showed that 82% of patients achieved the minimal clinically important difference (MCID) in their myasthenia gravis activities of daily living (MG-ADL) with a mean 4-point improvement in MG-ADL after receiving subcutaneous Briumvi at week 24. These early results support the continued development of Briumvi in indications beyond multiple sclerosis.
Briumvi generated sales of $201.3 million in the first quarter of 2026, reflecting a 68.2% year-over-year increase. Successful development in additional indications could provide a meaningful boost to Briumvi sales over the long term.
TGTX Price Performance
Year to date, shares of TG Therapeutics have rallied 45.5% against the industry’s decline of 2.5%.
Image Source: Zacks Investment Research
TGTX’s Phase II Study on Briumvi in MG
The phase II study, which is expected to enroll around 120 patients, is evaluating the safety and efficacy of Briumvi in maintaining clinical response in patients with MG who initially respond to treatment with the FcRn inhibitor Vyvgart.
The study is designed to assess whether Briumvi can safely help maintain the treatment benefits achieved with Vyvgart in the given patient population.
The study will initially use the Briumvi IV dosing regimen, while the SC version of Briumvi will be introduced later, after the completion of ongoing pharmacokinetic bridging studies in multiple sclerosis.
The primary endpoint of the study is to check the time to clinical worsening, defined as either a 2-point or greater increase in the MG-ADL score from baseline or a myasthenic crisis that requires hospitalization.
ARGX’s Vyvgart is approved for treating all adult patients with generalized myasthenia gravis, regardless of antibody status. Argenx recorded $1.3 billion in global Vyvgart sales in the first quarter of 2026, up 63% year over year.
TG Therapeutics, Inc. Price
TG Therapeutics, Inc. price | TG Therapeutics, Inc. Quote
TGTX's Zacks Rank & Stocks to Consider
TG Therapeutics currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are Liquidia Corporation LQDA and Immunocore IMCR, each currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Over the past 60 days, estimates for Liquidia’s 2026 EPS have increased to $2.97 from $1.50. Over the same period, EPS estimates for 2027 have risen to $4.81 from $2.91. LQDA shares have surged 85.6% year to date.
Liquidia’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average surprise being 54.40%.
Over the past 60 days, estimates for Immunocore’s 2026 bottom line have improved from a loss of 88 cents per share to earnings of 6 cents. Over the same period, EPS estimates for 2027 have risen from 24 cents to 87 cents. IMCR shares have lost 17.8% year to date.
Immunocore’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average surprise being 46.66%.
Zacks' Research Chief Names "Stock Most Likely to Double"
Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.
This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.
Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
TG Therapeutics, Inc. (TGTX): Free Stock Analysis Report
argenex SE (ARGX): Free Stock Analysis Report
Liquidia Corporation (LQDA): Free Stock Analysis Report
Immunocore Holdings PLC Sponsored ADR (IMCR): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).